The immunohistochemistry of CD3+, CD8+, CD68+, CD20+ and FOXP3+ cells from NSCLC treated with ICI revealed that expression of FOXP3+ was associated with shorter progression-free survival (14.8 vs. 1.8 months, p = 0.003, HR 8.7 and 95% CI 1.55–48.7) and worse overall survival (22.0 vs. 8.3 months, p = 0.035, HR 3.86 and 95% CI 1.01–14.8) [32]. Here, FOXP3 is linked to non-small cell lung carcinoma.